Ontology highlight
ABSTRACT:
SUBMITTER: Zeiser R
PROVIDER: S-EPMC4854652 | biostudies-literature | 2015 Oct
REPOSITORIES: biostudies-literature
Zeiser R R Burchert A A Lengerke C C Verbeek M M Maas-Bauer K K Metzelder S K SK Spoerl S S Ditschkowski M M Ecsedi M M Sockel K K Ayuk F F Ajib S S de Fontbrune F S FS Na I-K IK Penter L L Holtick U U Wolf D D Schuler E E Meyer E E Apostolova P P Bertz H H Marks R R Lübbert M M Wäsch R R Scheid C C Stölzel F F Ordemann R R Bug G G Kobbe G G Negrin R R Brune M M Spyridonidis A A Schmitt-Gräff A A van der Velden W W Huls G G Mielke S S Grigoleit G U GU Kuball J J Flynn R R Ihorst G G Du J J Blazar B R BR Arnold R R Kröger N N Passweg J J Halter J J Socié G G Beelen D D Peschel C C Neubauer A A Finke J J Duyster J J von Bubnoff N N
Leukemia 20150731 10
Despite major improvements in allogeneic hematopoietic cell transplantation over the past decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (GVHD) cause high mortality. Preclinical evidence indicates the potent anti-inflammatory properties of the JAK1/2 inhibitor ruxolitinib. In this retrospective survey, 19 stem cell transplant centers in Europe and the United States reported outcome data from 95 patients who had received ruxolitinib as salvage therapy ...[more]